drugset / Trial / NCT06518538
Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
Open label, randomized phase II study to evaluate efficacy and safety of CPI-613 + mFFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years
Timeline
- Start
- 2024-08-15
- Primary completion
- 2026-08
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPI-613 | Small molecule | 500 mg/m2 | Intravenous |
| Background | Irinotecan | Small molecule | 120 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 400 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 60 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 2200 mg/m2 | — |